drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Humanized afucosylated IgG1 monoclonal antibody targeting interleukin‑5 receptor alpha (IL‑5Rα); blocks IL‑5/IL‑5R signaling and induces Fc-mediated ADCC to deplete eosinophils (and basophils), reducing type 2 eosinophilic inflammation. Administered 30 mg subcutaneously q4w ×3 then q8w.
nci_thesaurus_concept_id
C88594
nci_thesaurus_preferred_term
Benralizumab
nci_thesaurus_definition
An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.
drug_mesh_term
Benralizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized afucosylated IgG1 monoclonal antibody against IL‑5 receptor alpha (IL‑5Rα) that blocks IL‑5/IL‑5R signaling and leverages enhanced Fc‑mediated ADCC to deplete IL‑5Rα–expressing eosinophils (and basophils), thereby reducing type 2 eosinophilic inflammation.
drug_name
Benralizumab
nct_id_drug_ref
NCT06288516